Kyoung Mee Kim

List of Publications by Citations

319 papers	10,331 citations	50 h-index	90 g-index
337 ext. papers	12,806 ext. citations	5.2 avg, IF	5.87 L-index

#	Paper	IF	Citations
319	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. *Nature Medicine*, **2015**, 21, 449-56	50.5	1031
318	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. *Nature Medicine*, **2018**, 24, 1449-1458	50.5	577
317	Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. *Journal of Clinical Oncology*, **2012**, 30, 268-73	2.2	537
316	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. *Journal of Clinical Oncology*, **2015**, 33, 3130-6	2.2	271
315	Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. *Gut*, **2014**, 63, 236-43	19.2	238
314	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. *Cancer Discovery*, **2018**, 8, 37-48	24.4	162
313	Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. *Cancer Research and Treatment*, **2012**, 44, 157-65	5.2	140
312	Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. *Nature Communications*, **2014**, 5, 5477	17.4	130
311	Comparing MR imaging and CT in the staging of gastric carcinoma. *American Journal of Roentgenology*, **2000**, 174, 1551-7	5.4	126
310	Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. *Gastroenterology*, **2010**, 139, 84-92.e2	13.3	125
309	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. *Journal of Clinical Oncology*, **2019**, 37, 3392-3400	2.2	123
308	Low-level microsatellite instability in most colorectal carcinomas. *Cancer Research*, **2002**, 62, 1166-70	10.1	122
307	Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. *American Journal of Surgical Pathology*, **2011**, 35, 1274-86	6.7	107
306	Progressive methylation during the serrated neoplasia pathway of the colorectum. *Modern Pathology*, **2005**, 18, 170-8	9.8	103
305	MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. *Modern Pathology*, **2013**, 26, 1632-41	9.8	101
304	Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. *Oncology Reports*, **2011**, 25, 1517-24	3.5	99
303	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. *Nature Genetics*, **2018**, 50, 1399-1411	36.3	94

302	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. *Nature Communications*, **2017**, 8, 1377	17.4	92
301	Identification of ROS1 rearrangement in gastric adenocarcinoma. *Cancer*, **2013**, 119, 1627-35	6.4	92
300	KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. *American Journal of Surgical Pathology*, **2010**, 34, 667-75	6.7	92
299	Methylation reveals a niche: stem cell succession in human colon crypts. *Oncogene*, **2002**, 21, 5441-9	9.2	92
298	Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. *Cancer Research and Treatment*, **2016**, 48, 1155-1166	5.2	92
297	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. *Nature Genetics*, **2018**, 50, 979-989	36.3	90
296	Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients. *American Journal of Surgical Pathology*, **2007**, 31, 224-32	6.7	87
295	Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. *PLoS Genetics*, **2015**, 11, e1005467	6	86
294	Deregulation of immune response genes in patients with Epstein-Barr virus-associated gastric cancer and outcomes. *Gastroenterology*, **2015**, 148, 137-147.e9	13.3	85
293	Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. *Clinical Cancer Research*, **2016**, 22, 3831-40	12.9	82
292	Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. *Journal of Clinical Investigation*, **2014**, 124, 5145-58	15.9	81
291	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. *Journal of Cancer*, **2016**, 7, 484-9	4.5	81
290	Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. *PLoS ONE*, **2014**, 9, e90133	3.7	79
289	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. *Cancer Discovery*, **2019**, 9, 1388-1405	24.4	78
288	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. *Oncotarget*, **2015**, 6, 40360-9	3.3	77
287	Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma. *Modern Pathology*, **2008**, 21, 1533-41	9.8	75
286	Differential Proteomic Analysis of Human Saliva using Tandem Mass Tags Quantification for Gastric Cancer Detection. *Scientific Reports*, **2016**, 6, 22165	4.9	73
285	The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. *BMC Cancer*, **2011**, 11, 344	4.8	73

284	Gastrointestinal stromal tumors in Koreans: its incidence and the clinical, pathologic and immunohistochemical findings. *Journal of Korean Medical Science*, **2005**, 20, 977-84	4.7	73
283	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. *Clinical Cancer Research*, **2019**, 25, 7035-7045	12.9	72
282	The prognostic significance of tumor-associated stroma in invasive breast carcinoma. *Tumor Biology* , **2012**, 33, 1573-80	2.9	69
281	Genetic evidence for the multi-step progression of mixed glandular-neuroendocrine gastric carcinomas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2002**, 440, 85-93	5.1	68
280	Surveillance strategy based on the incidence and patterns of recurrence after curative endoscopic submucosal dissection for early gastric cancer. *Endoscopy*, **2015**, 47, 784-93	3.4	66
279	High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. *PLoS ONE*, **2012**, 7, e38892	3.7	66
278	Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. *Modern Pathology*, **2013**, 26, 677-84	9.8	61
277	Genetic classification of intestinal-type and diffuse-type gastric cancers based on chromosomal loss and microsatellite instability. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2003**, 443, 491-500	5.1	57
276	Enhanced stem cell survival in familial adenomatous polyposis. *American Journal of Pathology*, **2004** , 164, 1369-77	5.8	56
275	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. *Oncotarget*, **2017**, 8, 77415-77423	3.3	55
274	Prognostic implications of microsatellite genotypes in gastric carcinoma. *International Journal of Cancer*, **2000**, 89, 378-83	7.5	54
273	Effect of rescue surgery after non-curative endoscopic resection of early gastric cancer. *British Journal of Surgery*, **2015**, 102, 1394-401	5.3	52
272	Clinical presentation and risk factors for cytomegalovirus colitis in immunocompetent adult patients. *Clinical Infectious Diseases*, **2015**, 60, e20-6	11.6	51
271	Small submucosal tumors of the stomach: differentiation of gastric schwannoma from gastrointestinal stromal tumor with CT. *Korean Journal of Radiology*, **2012**, 13, 425-33	6.9	51
270	DOG1 and PKC- are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. *Modern Pathology*, **2011**, 24, 866-75	9.8	51
269	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. *Oncotarget*, **2017**, 8, 13320-13328	3.3	50
268	FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. *Modern Pathology*, **2016**, 29, 1095-103	9.8	49
267	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. *Oncotarget*, **2015**, 6, 28211-22	3.3	48

266	P21-activated kinase 4 overexpression in metastatic gastric cancer patients. *Translational Oncology*, **2011**, 4, 345-9	4.9	46
265	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. *Oncotarget*, **2015**, 6, 39028-35	3.3	46
264	MicroRNA Expression Profiles in Gastric Carcinogenesis. *Scientific Reports*, **2018**, 8, 14393	4.9	46
263	The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. *Oncotarget*, **2016**, 7, 7940-51	3.3	45
262	Molecular Testing for Gastrointestinal Cancer. *Journal of Pathology and Translational Medicine*, **2017**, 51, 103-121	2.9	44
261	Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. *Annals of Surgery*, **2008**, 247, 1011-8	7.8	44
260	Increased Risk for Malignancies in 131 Affected Mutation Carriers. *Frontiers in Immunology*, **2018**, 9, 2012	5.4	44
259	ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).. *Journal of Clinical Oncology*, **2019**, 37, 4001-4001	2.2	42
258	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. *Oncotarget*, **2015**, 6, 25619-30	3.3	42
257	Glomus tumor of the stomach: a clinicopathologic analysis of 10 cases and review of the literature. *Gut and Liver*, **2012**, 6, 52-7	4.8	42
256	Outcomes of endoscopic submucosal dissection for differentiated-type early gastric cancer with histological heterogeneity. *Gastric Cancer*, **2015**, 18, 618-26	7.6	41
255	Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003-2004. *Journal of Korean Medical Science*, **2010**, 25, 853-62	4.7	41
254	Tracing origin of serrated adenomas with BRAF and KRAS mutations. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2005**, 447, 597-602	5.1	41
253	Epstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune Response. *Journal of Gastric Cancer*, **2016**, 16, 1-7	3.2	41
252	Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. *ESMO Open*, **2018**, 3, e000326	6	40
251	Deamination Effects in Formalin-Fixed, Paraffin-Embedded Tissue Samples in the Era of Precision Medicine. *Journal of Molecular Diagnostics*, **2017**, 19, 137-146	5.1	39
250	Genotyping possible polymorphic variants of human mismatch repair genes in healthy Korean individuals and sporadic colorectal cancer patients. *Familial Cancer*, **2004**, 3, 129-37	3	39
249	PKCtheta expression in gastrointestinal stromal tumor. *Modern Pathology*, **2006**, 19, 1480-6	9.8	37

248	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. *Oncotarget*, **2016**, 7, 43492-43503	3.3	37
247	Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor RNF43 in early gastric carcinogenesis. *Journal of Pathology*, **2016**, 240, 304-314	9.4	35
246	Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninvasive Detection of Gastric Cancer. *Clinical Chemistry*, **2018**, 64, 1513-1521	5.5	35
245	Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. *Oncotarget*, **2015**, 6, 38372-80	3.3	35
244	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. *Cancer Discovery*, **2017**, 7, 630-651	24.4	34
243	Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. *Targeted Oncology*, **2015**, 10, 597-601	5	34
242	Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers. *International Journal of Cancer*, **2015**, 136, 1568-78	7.5	34
241	Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. *Cancer Research and Treatment*, **2012**, 44, 85-96	5.2	34
240	The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. *Scientific Reports*, **2015**, 5, 9289	4.9	33
239	High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. *PLoS ONE*, **2012**, 7, e41655	3.7	33
238	Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. *Pathology International*, **2008**, 58, 17-25	1.8	33
237	Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. *Oncotarget*, **2017**, 8, 15014-15022	3.3	32
236	Early gastric cancer with a mixed-type Lauren classification is more aggressive and exhibits greater lymph node metastasis. *Journal of Gastroenterology*, **2017**, 52, 594-601	6.9	32
235	Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. *Asia-Pacific Journal of Clinical Oncology*, **2014**, 10, 297-307	1.9	32
234	Fractional allelic loss in gastric carcinoma correlates with growth patterns. *Oncogene*, **1998**, 17, 2655-9	9.2	32
233	High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. *PLoS ONE*, **2014**, 9, e111693	3.7	32
232	A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. *Annals of Oncology*, **2021**, 32, 368-374	10.3	32
231	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. *Frontiers in Oncology*, **2020**, 10, 314	5.3	31

230	A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages. *Annals of Surgical Oncology*, **2013**, 20 Suppl 3, S477-84	3.1	31
229	Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. *PLoS ONE*, **2013**, 8, e82770	3.7	31
228	Tracing ancestry with methylation patterns: most crypts appear distantly related in normal adult human colon. *BMC Gastroenterology*, **2004**, 4, 8	3	31
227	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. *Oncotarget*, **2015**, 6, 24320-32	3.3	31
226	Endoscopic submucosal dissection of early gastric cancer. *Gut and Liver*, **2011**, 5, 418-26	4.8	30
225	A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. *PLoS ONE*, **2013**, 8, e54644	3.7	30
224	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. *Oncotarget*, **2016**, 7, 4024-35	3.3	30
223	Plexiform angiomyxoid myofibroblastic tumor of the stomach: report of two cases and review of the literature. *Korean Journal of Pathology*, **2012**, 46, 292-6		30
222	The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencing. *Scientific Reports*, **2016**, 6, 26732	4.9	29
221	Esophageal parakeratosis mimicking endoscopic appearance of superficial esophageal neoplastic lesion such as dysplasia. *Digestive Endoscopy*, **2012**, 24, 117-9	3.7	29
220	Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. *Clinical Cancer Research*, **2009**, 15, 291-8	12.9	29
219	Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. *Investigational New Drugs*, **2013**, 31, 1580-6	4.3	28
218	HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. *International Journal of Cancer*, **2015**, 136, 1629-35	7.5	28
217	Endoscopic resection for undifferentiated early gastric cancer: focusing on histologic discrepancies between forceps biopsy-based and endoscopic resection specimen-based diagnosis. *Digestive Diseases and Sciences*, **2014**, 59, 2536-43	4	28
216	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. *OncoImmunology*, **2017**, 6, e1356150	7.2	27
215	Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. *Pathology*, **2012**, 44, 216-20	1.6	27
214	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. *Cancer Discovery*, **2021**, 11, 2168-2185	24.4	27
213	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis. *Molecular Cancer Therapeutics*, **2018**, 17, 838-848	6.1	26

212	Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. *Investigational New Drugs*, **2014**, 32, 535-41	4.3	26
211	Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. *Molecular Cancer Therapeutics*, **2014**, 13, 2527-36	6.1	26
210	Clinical significance of gastritis cystica profunda and its association with Epstein-Barr virus in gastric cancer. *Cancer*, **2012**, 118, 5227-33	6.4	26
209	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. *Journal of Gastric Cancer*, **2016**, 16, 105-10	3.2	26
208	Epstein-Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma. *Gastric Cancer*, **2016**, 19, 852-9	7.6	25
207	Bridging genomics and phenomics of gastric carcinoma. *International Journal of Cancer*, **2019**, 145, 2407-2417	7.3	25
206	Preoperative predictive factors for gastrointestinal stromal tumors: analysis of 375 surgically resected gastric subepithelial tumors. *Journal of Gastrointestinal Surgery*, **2015**, 19, 631-8	3.3	24
205	Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. *Acta Oncologica*, **2012**, 51, 528-36	3.2	24
204	Composite glandular-endocrine cell carcinomas of the stomach: clinicopathologic and methylation study. *Apmis*, **2005**, 113, 569-76	3.4	24
203	Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene. *PLoS ONE*, **2012**, 7, e34456	3.7	24
202	The Korean guideline for gastric cancer screening. *Journal of the Korean Medical Association*, **2015**, 58, 373	0.5	23
201	High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. *Pathology Research and Practice*, **2020**, 216, 152881	3.4	22
200	Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. *Targeted Oncology*, **2013**, 8, 271-80	5	22
199	Management strategy for small duodenal carcinoid tumors: does conservative management with close follow-up represent an alternative to endoscopic treatment?. *Digestion*, **2013**, 87, 247-53	3.6	22
198	Anti-Helicobacter pylori Antibody Profiles in Epstein-Barr virus (EBV)-Positive and EBV-Negative Gastric Cancer. *Helicobacter*, **2016**, 21, 153-7	4.9	22
197	Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. *Translational Oncology*, **2018**, 11, 37-42	4.9	22
196	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. *Translational Oncology*, **2017**, 10, 469-475	4.9	21
195	Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling. *Scientific Reports*, **2014**, 4, 3623	4.9	21

194	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. *Scientific Reports*, **2014**, 4, 7592	4.9	21
193	Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea. *Asia-Pacific Journal of Clinical Oncology*, **2011**, 7, 293-9	1.9	21
192	Relationship between intratumor histological heterogeneity and genetic abnormalities in gastric carcinoma with microsatellite instability. *International Journal of Cancer*, **1999**, 82, 782-8	7.5	21
191	The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. *Oncotarget*, **2015**, 6, 33358-68	3.3	21
190	CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. *Journal of Gastrointestinal Oncology*, **2014**, 5, 447-56	2.8	21
189	Detecting Primary KIT Mutations in Presurgical Plasma of Patients with Gastrointestinal Stromal Tumor. *Molecular Diagnosis and Therapy*, **2016**, 20, 347-51	4.5	21
188	Characterization of Human Salivary Extracellular RNA by Next-generation Sequencing. *Clinical Chemistry*, **2018**, 64, 1085-1095	5.5	20
187	Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. *Journal of Korean Medical Science*, **2010**, 25, 1543-52	4.7	20
186	Biomarkers for gastric cancer: molecular classification revisited. *Precision and Future Medicine*, **2017** , 1, 59-68	1.1	20
185	Gastrointestinal stromal tumours: correlation of modified NIH risk stratification with diffusion-weighted MR imaging as an imaging biomarker. *European Journal of Radiology*, **2015**, 84, 33-40	4.7	19
184	Development of mesenchymal subtype gene signature for clinical application in gastric cancer. *Oncotarget*, **2017**, 8, 66305-66315	3.3	19
183	Epstein-Barr virus-associated lymphoepithelioma-like early gastric carcinomas and endoscopic submucosal dissection: case series. *World Journal of Gastroenterology*, **2014**, 20, 1365-70	5.6	19
182	Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters. *Cancer Research and Treatment*, **2015**, 47, 813-22	5.2	19
181	Lymphoepithelioma-like carcinoma: a distinct type of gastric cancer. *Journal of Surgical Research*, **2015**, 194, 458-463	2.5	18
180	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. *Gastric Cancer*, **2018**, 21, 1064-1070	7.6	18
179	Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor. *Tumor Biology*, **2012**, 33, 1645-51	2.9	18
178	Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer **2021**, 9,		18
177	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). *Journal of Cancer*, **2017**, 8, 1395-1399	4.5	17

176	Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. *Gastric Cancer*, **2019**, 22, 363-368	7.6	17
175	Feasibility and Diagnostic Yield of Endoscopic Ultrasonography-Guided Fine Needle Biopsy With a New Core Biopsy Needle Device in Patients With Gastric Subepithelial Tumors. *Medicine (United States)*, **2015**, 94, e1622	1.8	17
174	Mucinous gastric cancer presents with more advanced tumor stage and weaker □catenin expression than nonmucinous cancer. *Annals of Surgical Oncology*, **2010**, 17, 3053-8	3.1	17
173	Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors. *Oncotarget*, **2016**, 7, 6538-51	3.3	17
172	MerTK is a novel therapeutic target in gastric cancer. *Oncotarget*, **2017**, 8, 96656-96667	3.3	17
171	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. *Clinical Cancer Research*, **2021**, 27, 4700-4709	12.9	17
170	Lymphovascular invasion and lymph node metastasis rates in papillary adenocarcinoma of the stomach: implications for endoscopic resection. *Gastric Cancer*, **2018**, 21, 680-688	7.6	16
169	Filiform serrated adenoma is an unusual, less aggressive variant of traditional serrated adenoma. *Pathology*, **2012**, 44, 18-23	1.6	16
168	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center□s experiences. *Oncotarget*, **2017**, 8, 42478-42486	3.3	16
167	Overexpression of MAPK15 in gastric cancer is associated with copy number gain and contributes to the stability of c-Jun. *Oncotarget*, **2015**, 6, 20190-203	3.3	16
166	A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth. *Oncotarget*, **2016**, 7, 28670-83	3.3	16
165	Fetal-type gastrointestinal adenocarcinoma: a morphologically distinct entity with unfavourable prognosis. *Journal of Clinical Pathology*, **2018**, 71, 221-227	3.9	16
164	Predictive factors for lymph node metastasis in early gastric cancer with lymphatic invasion after endoscopic resection. *Surgical Endoscopy and Other Interventional Techniques*, **2017**, 31, 4419-4424	5.2	15
163	Detection of (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. *Frontiers in Oncology*, **2019**, 9, 212	5.3	15
162	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. *Journal of Clinical Oncology*, **2019**, 37, 66-66	2.2	15
161	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. *Oncology*, **2019**, 97, 38-43	3.6	14
160	Clinicopathological factors of multiple lateral margin involvement after endoscopic submucosal dissection for early gastric cancer. *Surgical Endoscopy and Other Interventional Techniques*, **2015**, 29, 3460-8	5.2	14
159	Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer. *Cancer Chemotherapy and Pharmacology*, **2012**, 69, 1333-8	3.5	14

158	GAGE12 mediates human gastric carcinoma growth and metastasis. *International Journal of Cancer*, **2015**, 136, 2284-92	7.5	13
157	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. *ESMO Open*, **2016**, 1, e000009	6	13
156	A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single-Nucleotide Variant Detection. *Journal of Molecular Diagnostics*, **2017**, 19, 651-658	5.1	13
155	Gastrointestinal stromal tumors in children and young adults: a clinicopathologic and molecular genetic study of 22 Korean cases. *Apmis*, **2013**, 121, 938-44	3.4	13
154	PolyA deletions in hereditary nonpolyposis colorectal cancer: mutations before a gatekeeper. *American Journal of Pathology*, **2002**, 160, 1503-6	5.8	13
153	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. *Oncotarget*, **2017**, 8, 3237-3245	3.3	13
152	MicroRNA signatures associated with lymph node metastasis in intramucosal gastric cancer. *Modern Pathology*, **2021**, 34, 672-683	9.8	13
151	Diagnostic group classifications of gastric neoplasms by endoscopic resection criteria before and after treatment: real-world experience. *Surgical Endoscopy and Other Interventional Techniques*, **2016**, 30, 3987-93	5.2	12
150	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. *Oncotarget*, **2017**, 8, 105727-105734	5.3	12
149	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. *Molecular Diagnosis and Therapy*, **2016**, 20, 375-83	4.5	12
148	Clinicopathological Features and Prognosis of Mixed-Type T1a Gastric Cancer Based on Lauren's Classification. *Annals of Surgical Oncology*, **2016**, 23, 784-791	3.1	12
147	MMR protein immunohistochemistry and microsatellite instability in gastric cancers. *Pathology*, **2019**, 51, 110-113	1.6	12
146	Comparison of Long-Term Outcomes After Non-curative Endoscopic Resection in Older Patients with Early Gastric Cancer. *Annals of Surgical Oncology*, **2017**, 24, 2624-2631	3.1	11
145	High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. *Pathology Research and Practice*, **2020**, 216, 152878	3.4	11
144	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. *Clinical Colorectal Cancer*, **2018**, 17, 140-146	3.8	11
143	Feasibility of Endoscopic Resection in Early Gastric Cancer with Lymphovascular Invasion. *Annals of Surgical Oncology*, **2019**, 26, 449-455	3.1	11
142	Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. *JCO Clinical Cancer Informatics*, **2018**, 2, 1-14	5.2	11
141	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 1758835921992992	5.4	11

140	CCNE1 amplification is associated with liver metastasis in gastric carcinoma. *Pathology Research and Practice*, **2019**, 215, 152434	3.4	10
139	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). *Journal of Cancer Research and Clinical Oncology*, **2016**, 142, 1231-7	4.9	10
138	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. *Oncologist*, **2017**, 22, 1169-1177	5.7	10
137	Neuroendocrine tumor in gastric adenoma: a diagnostic pitfall mimicking invasive adenocarcinoma. *Diagnostic Pathology*, **2012**, 7, 102	3	10
136	Pituitary aspergillosis mimicking pituitary tumor. *American Journal of Roentgenology*, **2000**, 175, 1570-2	5.4	10
135	IKK and TBK1 expression in gastric cancer. *Oncotarget*, **2017**, 8, 16233-16242	3.3	10
134	Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. *Cancer Research and Treatment*, **2015**, 47, 738-46	5.2	10
133	Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma. *Gastric Cancer*, **2021**, 24, 858-867	7.6	10
132	PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. *Modern Pathology*, **2021**, 34, 1719-1727	9.8	10
131	NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines. *Journal of Cancer*, **2018**, 9, 3032-3037	4.5	10
130	CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer. *Annals of Surgical Oncology*, **2014**, 21, 1099-106	3.1	9
129	Sporadic colorectal carcinomas with low-level microsatellite instability in Korea: do they form a distinct subgroup with distinguished clinicopathological features?. *Journal of Surgical Oncology*, **2009**, 99, 351-5	2.8	9
128	Evidence for two modes of allelic loss: multifocal analysis on both early and advanced gastric carcinomas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2001**, 438, 31-8	5.1	9
127	Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. *Gastric Cancer*, **2021**, 24, 457-466	7.6	9
126	Identification of risk factors for sessile and traditional serrated adenomas of the colon by using big data analysis. *Journal of Gastroenterology and Hepatology (Australia)*, **2018**, 33, 1039-1046	4	9
125	Computational measurement of tumor immune microenvironment in gastric adenocarcinomas. *Scientific Reports*, **2018**, 8, 13887	4.9	9
124	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. *Genome Medicine*, **2021**, 13, 11	14.4	9
123	Comprehensive pharmacogenomic characterization of gastric cancer. *Genome Medicine*, **2020**, 12, 17	14.4	8

122	Neurofibroma of the Colon: A Diagnostic Mimicker of Gastrointestinal Stromal Tumor. *Case Reports in Gastroenterology*, **2016**, 10, 674-678	1	8
121	One-dimensional and 2-dimensional tumor size measurement for prediction of lymph node metastasis in differentiated early gastric cancer with minute submucosal invasion. *Gastrointestinal Endoscopy*, **2017**, 85, 730-736	5.2	8
120	Comparison of Three BRAF Mutation Tests in Formalin-Fixed Paraffin Embedded Clinical Samples. *Korean Journal of Pathology*, **2013**, 47, 348-54		8
119	Outcomes of Endoscopic Submucosal Dissection for Early Gastric Cancer with Undifferentiated-Type Histology: A Clinical Simulation Using a Non-Selected Surgical Cohort. *Gut and Liver*, **2018**, 12, 263-270	4.8	8
118	Indication for endoscopic treatment based on the risk of lymph node metastasis in patients with Siewert type II/III early gastric cancer. *Gastric Cancer*, **2018**, 21, 672-679	7.6	8
117	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. *Journal of Gastric Cancer*, **2018**, 18, 348-355	3.2	8
116	Gastrointestinal stromal tumours of the oesophagus: a clinicopathological and molecular analysis of 27 cases. *Histopathology*, **2017**, 71, 805-812	7.3	7
115	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. *Translational Oncology*, **2015**, 8, 288-94	4.9	7
114	EBV infection and mismatch repair deficiency mediated by loss of hMLH1 expression contribute independently to the development of multiple synchronous gastric carcinomas. *Journal of Surgical Oncology*, **2012**, 106, 777-82	2.8	7
113	Silent Colonic Malakoplakia in a Living-Donor Kidney Transplant Recipient Diagnosed during Annual Medical Examination. *Korean Journal of Pathology*, **2013**, 47, 163-6		7
112	Peritumoral lymphoid cuff correlates well with lymph node enlargement in gastrointestinal schwannomas. *Oncotarget*, **2018**, 9, 12591-12598	3.3	7
111	PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors. *Journal of Pathology and Translational Medicine*, **2015**, 49, 23-9	2.9	7
110	PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2020**, 476, 243-250	5.1	7
109	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in -Amplified Gastric Cancer. *JCO Precision Oncology*, **2020**, 4,	3.6	7
108	Serrated adenoma of the stomach: a clinicopathologic, immunohistochemical, and molecular study of nine cases. *Histology and Histopathology*, **2013**, 28, 453-62	1.4	7
107	Gastric adenocarcinoma with enteroblastic differentiation should be differentiated from hepatoid adenocarcinoma: A study with emphasis on clear cells and clinicopathologic spectrum. *Pathology Research and Practice*, **2019**, 215, 152525	3.4	6
106	Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue. *Scientific Reports*, **2019**, 9, 9675	4.9	6
105	Exuberant squamous metaplasia of the gastric mucosa in a patient with gastric adenocarcinoma. *Diagnostic Pathology*, **2015**, 10, 46	3	6

104	Clinical usefulness of microsatellite instability test in Korean young patients with high-risk features associated with adenoma. *Clinics and Research in Hepatology and Gastroenterology*, **2012**, 36, 378-83	2.4	6
103	Tumor size predicts survival in mucinous gastric carcinoma. *Journal of Surgical Oncology*, **2012**, 106, 757-63	2.8	6
102	A Risk Prediction Model Based on Lymph-Node Metastasis in Poorly Differentiated-Type Intramucosal Gastric Cancer. *PLoS ONE*, **2016**, 11, e0156207	3.7	6
101	LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target. *Journal of Immunotherapy*, **2019**, 42, 279-283	5	6
100	Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. *Pathology Research and Practice*, **2020**, 216, 152947	3.4	6
99	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. *Translational Oncology*, **2019**, 12, 597-601	4.9	5
98	Circulating Antibodies against Epstein-Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 414-419	4	5
97	Young Age and Risk of Lymph Node Metastasis in Differentiated Type Early Gastric Cancer. *Annals of Surgical Oncology*, **2018**, 25, 2713-2719	3.1	5
96	Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas. *Diagnostic Pathology*, **2013**, 8, 121	3	5
95	Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. *Oncotarget* , **2017**, 8, 107492-107499	3.3	5
94	Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer. *Clinical and Translational Oncology*, **2021**, 1	3.6	5
93	Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. *Oncotarget*, **2016**, 7, 13797-809	3.3	5
92	A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer. *Cancer Research and Treatment*, **2020**, 52, 1153-1161	5.2	5
91	Novel mechanism of a CDH1 splicing mutation in a Korean patient with signet ring cell carcinoma. *BMB Reports*, **2011**, 44, 725-9	5.5	5
90	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920926796	5.4	5
89	Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy. *European Journal of Surgical Oncology*, **2020**, 46, 189-194	3.6	5
88	Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing: A Direct Comparison Study with Immunohistochemistry. *Journal of Molecular Diagnostics*, **2019**, 21, 612-622	5.1	4
87	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.. *Translational Cancer Research*, **2020**, 9, 3367-3374	0.3	4

86	A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling. *Frontiers in Oncology*, **2020**, 10, 225	5.3	4
85	Poorly differentiated component in gastric pinch biopsies predicts submucosal invasion. *Diagnostic Pathology*, **2014**, 9, 34	3	4
84	Multiplex mutation screening by mass spectrometry in gastrointestinal stromal tumours. *Pathology*, **2012**, 44, 460-4	1.6	4
83	Inter-observer Reproducibility in the Pathologic Diagnosis of Gastric Intraepithelial Neoplasia and Early Carcinoma in Endoscopic Submucosal Dissection Specimens: A Multi-center Study. *Cancer Research and Treatment*, **2019**, 51, 1568-1577	5.2	4
82	PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. *Cancers*, **2021**, 13,	6.6	4
81	A comparative study of telomerase activity and cytologic diagnosis in malignant ascites. *Analytical and Quantitative Cytopathology and Histopathology*, **2013**, 35, 146-51		4
80	Early Tumor-Immune Microenvironmental Remodeling and Response to Frontline Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer.. *Cancer Discovery*, **2021**,	24.4	4
79	PTEN Protein Loss and Loss-of-Function Mutations in Gastric Cancers: The Relationship with Microsatellite Instability, EBV, HER2, and PD-L1 Expression. *Cancers*, **2020**, 12,	6.6	3
78	Is endoscopic resection an alternative to surgery for early low-risk submucosal gastric cancers: analysis of a large surgical database. *Surgical Endoscopy and Other Interventional Techniques*, **2015**, 29, 1614-20	5.2	3
77	Stage IV early gastric cancer: two cases with microsatellite instability. *Langenbeckfs Archives of Surgery*, **2008**, 393, 105-9	3.4	3
76	Combined biomarker for prediction of response to an immune checkpoint inhibitor in metastatic gastric cancer. *Precision and Future Medicine*, **2019**, 3, 165-175	1.1	3
75	RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis. *Scientific Reports*, **2019**, 9, 19439	4.9	3
74	Effect of age on the clinical outcomes of patients with early gastric cancer with undifferentiated-type histology. *Surgery*, **2019**, 165, 802-807	3.6	3
73	MET is overexpressed in microsatellite instability-high gastric carcinoma. *Pathology Research and Practice*, **2019**, 215, 433-438	3.4	3
72	Gastric Inverted Polyps-Distinctive Subepithelial Lesions of the Stomach: Clinicopathologic Analysis of 12 Cases With an Emphasis on Neoplastic Potential. *American Journal of Surgical Pathology*, **2021** , 45, 680-689	6.7	3
71	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. *Journal of Gastrointestinal Oncology*, **2018**, 9, 1198-1206	2.8	3
70	Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study. *Translational Oncology*, **2019**, 12, 1488-1495	4.9	2
69	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. *Pathology Research and Practice*, **2020**, 216, 152820	3.4	2

68	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. *Journal of Oncology*, **2020**, 2020, 4659062	4.5	2
67	Dysregulated miRNA in a cancer-prone environment: A study of gastric non-neoplastic mucosa. *Scientific Reports*, **2020**, 10, 6600	4.9	2
66	CDH1 mutations in gastric cancers are not associated with family history. *Pathology Research and Practice*, **2020**, 216, 152941	3.4	2
65	Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. *Cancers*, **2020**, 12,	6.6	2
64	Measurement of tumor volume is not superior to diameter for prediction of lymph node metastasis in early gastric cancer with minute submucosal invasion. *Oncotarget*, **2017**, 8, 113758-113765	3.3	2
63	Recent advances in endoscopic diagnosis and treatment of gastric cancer. *Journal of the Korean Medical Association*, **2015**, 58, 191	0.5	2
62	Aggressive gastrointestinal stromal tumour of the oesophagus with homozygous KIT exon 11 deletion mutation. *Pathology*, **2012**, 44, 260-1	1.6	2
61	Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trial□ feasibility analysis.. *Journal of Clinical Oncology*, **2016**, 34, 11534-11534	2.2	2
60	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. *American Journal of Translational Research (discontinued)*, **2019**, 11, 4508-4515	3	2
59	Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial. *Precision and Future Medicine*, **2019**, 3, 24-29	1.1	2
58	Assessment of Gastritis Using Operative Link for Gastritis Assessment System. *The Korean Journal of Helicobacter and Upper Gastrointestinal Research*, **2013**, 13, 20	0.4	2
57	Negative Biopsy after Referral for Biopsy-Proven Gastric Cancer. *Gut and Liver*, **2016**, 10, 63-8	4.8	2
56	Correlation between RICTOR overexpression and amplification in advanced solid tumors. *Pathology Research and Practice*, **2020**, 216, 152734	3.4	2
55	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. *Radiotherapy and Oncology*, **2020**, 152, 19-25	5.3	2
54	Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. *Frontiers in Immunology*, **2021**, 12, 701668	8.4	2
53	Outcomes of endoscopic submucosal dissection for intestinal-type adenocarcinoma with anastomosing glands of the stomach. *Journal of Gastroenterology and Hepatology (Australia)*, **2020**, 35, 50-55	4	2
52	PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study. *Pathology Research and Practice*, **2021**, 218, 153338	3.4	2
51	Factors Associated With Host Immune Response and Number of Lymph Nodes: A Large Retrospective Cohort Study. *Annals of Surgical Oncology*, **2018**, 25, 3621-3628	3.1	2

50	Highly sensitive duplex MSI test and BAT40 germline polymorphism. *Apmis*, **2021**, 129, 607-615	3.4	2
49	Comparative analysis of microsatellite instability by next-generation sequencing, MSI PCR and MMR immunohistochemistry in 1942 solid cancers.. *Pathology Research and Practice*, **2022**, 233, 153874	3.4	2
48	Favorable Long-Term Outcomes of Endoscopic Submucosal Dissection for Differentiated-Type-Predominant Early Gastric Cancer with Histological Heterogeneity. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
47	An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. *Journal of Cancer*, **2017**, 8, 730-736	4.5	1
46	High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. *Journal of Cancer*, **2019**, 10, 3172-3178	4.5	1
45	Direct comparison of the next-generation sequencing and iTERT PCR methods for the diagnosis of TERT hotspot mutations in advanced solid cancers.. *BMC Medical Genomics*, **2022**, 15, 25	3.7	1
44	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. *Journal of Clinical Oncology*, **2017**, 35, e15610-e15610	2.2	1
43	Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatured gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.. *Journal of Clinical Oncology*, **2018**, 36, 4061-4061	2.2	1
42	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. *Journal of Clinical Oncology*, **2018**, 36, e14501-e14501	2.2	1
41	Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial.. *Journal of Clinical Oncology*, **2018**, 36, e16029-e16029	2.2	1
40	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. *Journal of Clinical Oncology*, **2019**, 37, 3104-3104	2.2	1
39	Epigenetic alternate promoter utilization and association with PD-L1 expression in EpsteinBarr virus positive gastric cancer.. *Journal of Clinical Oncology*, **2019**, 37, e15509-e15509	2.2	1
38	Single patient classifier as a prognostic biomarker in pT1N1 gastric cancer: Results from two large Korean cohorts. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2021**, 33, 583-591	3.8	1
37	Mesenteric Fibromatosis Mimicking Recurrence after Distal Gastrectomy for Gastric Cancer. *Journal of Gastric Cancer*, **2010**, 10, 79	3.2	1
36	Profiling of circulating tumor cells isolated from 105 metastatic gastric cancer patients revealed HER2 overexpression/activation for potential use in clinical setting.. *Journal of Clinical Oncology*, **2012**, 30, 10535-10535	2.2	1
35	IL-7RCD8 T Cells from Healthy Individuals Are Anergic with Defective Glycolysis. *Journal of Immunology*, **2020**, 205, 2968-2978	5.3	1
34	Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer. *Cancers*, **2021**, 13,	6.6	1
33	Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer. *European Radiology*, **2022**, 32, 1-11	8	1

32	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. *Journal of Cancer*, **2016**, 7, 2173-2178	4.5	1
31	Digital image analysis in pathologist-selected regions of interest predicts survival more accurately than whole-slide analysis: a direct comparison study in 153 gastric carcinomas. *Journal of Pathology: Clinical Research*, **2021**, 7, 42-51	5.3	1
30	Prognostic Value of Highly Expressed Type VII Collagen (COL7A1) in Patients With Gastric Cancer. *Pathology and Oncology Research*, **2021**, 27, 1609860	2.6	1
29	Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study. *Annals of Surgical Oncology*, **2021**, 28, 8908-8915	3.1	1
28	Deep learning-based virtual cytokeratin staining of gastric carcinomas to measure tumor-stroma ratio. *Scientific Reports*, **2021**, 11, 19255	4.9	1
27	Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches.. *Biomedicines*, **2022**, 10,	4.8	1
26	Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma.. *Frontiers in Oncology*, **2022**, 12, 856444	5.3	1
25	Risk-Scoring System for Prediction of Non-Curative Endoscopic Submucosal Dissection Requiring Additional Gastrectomy in Patients with Early Gastric Cancer.. *Journal of Gastric Cancer*, **2021**, 21, 368-378	3.2	0
24	Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2021**, 39, 3536-3536	2.2	0
23	Pathologic analyses of peritoneal nodules in gastric cancer patients during surgery-A single cancer center experience with diagnostic pitfalls. *Pathology Research and Practice*, **2019**, 215, 195-199	3.4	0
22	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing.. *Journal of Oncology*, **2022**, 2022, 9714570	4.5	0
21	High Frequency of Juxtamembrane Domain Mutation in Gastric Cancer.. *Cancer Genomics and Proteomics*, **2022**, 19, 105-112	3.3	0
20	Gastrointestinal stromal tumour with CDKN2A deletions: a report of three cases. *Pathology*, **2019**, 51, 537-539	1.6	
19	Filiform serrated adenoma: authorsR reply. *Pathology*, **2012**, 44, 386	1.6	
18	Two Gastric Cancers With Uncommon ALK Fusion Diagnosed With Comprehensive Panel Sequencing and Confirmed With Companion Diagnostic Assay. *AJSP Review and Reports*, **2022**, 27, 9-12	0	
17	Mycobiome analysis in fungal infected formalin-fixed and paraffin-embedded tissues for identification of pathogenic fungi: a pilot study. *F1000Research*,9, 758	3.6	
16	AuthorR correction. *American Journal of Roentgenology*, **2000**, 175, 556	5.4	
15	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. *Journal of Clinical Oncology*, **2018**, 36, e24234-e24234	2.2	

14	Detection of targetable fusions using FusionPlex in oncology patients.. *Journal of Clinical Oncology*, **2018**, 36, e24238-e24238	2.2
13	Novel target discovery in pembrolizumab-resistant gastric cancer using a comprehensive RNA-seq analysis pipeline.. *Journal of Clinical Oncology*, **2020**, 38, e16541-e16541	2.2
12	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. *Journal of Clinical Oncology*, **2014**, 32, 4008-4008	2.2
11	Comprehensive genomic profiling of metastatic gastric cancer undergoing palliative chemotherapy at Samsung Medical Center using custom targeted deep sequencing (CancerSCAN). *Journal of Clinical Oncology*, **2015**, 33, e22173-e22173	2.2
10	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. *Journal of Clinical Oncology*, **2015**, 33, e22241-e22241	2.2
9	Development and validation of sensitive and selective biomarker for early detection and prognostic system of colorectal cancer using aptamer biochip.. *Journal of Clinical Oncology*, **2015**, 33, e22124-e22124	2.2
8	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. *Journal of Clinical Oncology*, **2017**, 35, e14622-e14622	2.2
7	Esophageal Gland Duct Adenoma. *Korean Journal of Pathology*, **2011**, 45, S45	
6	SSTR2A Protein Expression in Neuroendocrine Neoplasms of the Colorectum. *Korean Journal of Pathology*, **2011**, 45, 276	
5	Profiling of activated receptor tyrosine kinases in advanced gastric cancers identifies patients with poor prognosis.. *Journal of Clinical Oncology*, **2012**, 30, 4011-4011	2.2
4	DNA-protein biomarkers for immunotherapy in the era of precision oncology. *Journal of Pathology and Translational Medicine*, **2021**, 55, 26-32	2.9
3	Clinical feasibility and oncologic safety of primary endoscopic submucosal dissection for clinical submucosal invasive early gastric cancer. *Journal of Cancer Research and Clinical Oncology*, **2021**, 147, 3051-3061	4.9
2	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. *Journal of Cancer Research and Clinical Oncology*, **2021**, 1	4.9
1	ASO Video Abstract: Microsatellite Instability and the Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer-A Multi-cohort Study. *Annals of Surgical Oncology*, **2021**, 28, 688	3.1